Ocugen price target raised to $22 from $15 at Lucid Capital
Lucid Capital analyst Elemer Piros raised the firm’s price target on Ocugen (OCGN) to $22 from $15 and keeps a Buy rating on the shares. The company announced positive preliminary Phase 2 data for OCU410 in geographic atrophy, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on OCGN:
- Ocugen’s Gene Therapy Pipeline Dominates Earnings Call
- Ocugen: Late-Stage Retinal Pipeline and 2027–2028 Approval Catalysts Underpin Buy-Rated Risk‑Reward
- Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value
- Ocugen Seeks Court Validation of Charter Amendment Dispute
- Ocugen reports Q4 EPS (6c), consensus (6c)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
LAZARD, INC. <LAZ.N>: KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
LAZARD, INC. : KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
What Stocks Will Shine When the AI Bubble Bursts? John Rogers Says Look to Smucker's
GFL ENVIRONMENTAL INC. <GFL.TO>: CIBC CUTS TARGET PRICE TO C$77 FROM C$82
GFL ENVIRONMENTAL INC. : CIBC CUTS TARGET PRICE TO C$77 FROM C$82
Gold edges higher after hitting a two-month low
Crypto prices
More
